Phaseline

Targets › IGKC

IGKC (Immunoglobulin kappa constant): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2028.

Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. (UniProt, P01834)

Open in Phaseline: the race on IGKC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peter MacCallum Cancer Centre, AustraliaPMCC-COE-KMA
anti-KMA (kappa light chain) CAR-T cell therapy
IGKCPhase 1Relapsed/Refractory Multiple MyelomaSep 2028

Conditions

Relapsed/Refractory Multiple Myeloma (1)

Modalities

protein or peptide (1)

Companies

Peter MacCallum Cancer Centre, Australia (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.